Full-Time
Corporate Paralegal
Updated on 8/7/2026
Cencora
10,001+ employees
Global pharmaceutical distribution and services provider
No salary listed
Conshohocken, PA, USA
In Person
 Legal & Compliance (1) |
|---|
Get referred to Cencora
See people who can refer or advise you
- Requires good research, writing, communication, and computer skills.
- Requires a minimum of five or more years of progressively responsible and directly related experience.
- The candidate must be familiar with a variety of the field's concepts, practices, and legal procedures.
- The candidate must be able to work independently.
- The candidate must have excellent project management and research skills.
- The candidate must be able to communicate effectively both orally and in writing.
- The candidate must have excellent interpersonal skills.
- The candidate must demonstrate strong judgment and the ability to resolve issues effectively.
- The candidate must have strong organizational skills and attention to detail.
- The candidate must have strong computer skills and knowledge of Microsoft Word, Excel, and PowerPoint.
- Organize and maintain corporate minute books and records, and attend to related formalities for Cencora business units.
- Work with the Treasury Department on banking matters.
- Prepare Secretary's certificates and handle matters required to complete and close corporate acquisitions, divestitures, financings, and other transactions.
- Help Cencora comply with applicable federal and state healthcare regulatory frameworks, including fraud and abuse laws, pricing regulations, privacy requirements, and government program obligations.
- Assist with internal monitoring activities, audits, and investigations related to healthcare compliance.
- Support responses to government inquiries, audits, and enforcement actions.
- Assist in developing training materials related to healthcare compliance.
- Monitor and analyze developments in healthcare laws, regulations, and enforcement trends.
- Assist in drafting and updating compliance policies, standard operating procedures, and internal guidance documents.
- Assist with project management of corporate and healthcare projects.
- Experience in a medium to large law firm or within the legal department of a public company.
Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pennsylvania
Founded
1907
Get referred to Cencora
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 5, 2026 results raised fiscal 2026 EPS guidance to $17.75-$17.95.
- July 31, 2026 credit facility expansion to $7 billion strengthens liquidity through 2031.
- Specialty medicine demand and GLP-1 volume lifted third-quarter revenue to $84.75 billion.
What critics are saying
- $4.2 billion opioid liability remains outstanding as of June 30, 2026.
- The 2024 Cencora data breach settlement keeps cybersecurity and trust damage visible through 2026.
- Specialty and GLP-1 concentration creates margin pressure if manufacturer pricing or mix shifts again.
What makes Cencora unique
- Cencora owns irreplaceable pharmaceutical distribution scale across U.S. Healthcare and International networks.
- February 2026 OneOncology deepens specialty oncology workflows and physician practice integration.
- Nucleus inventory tooling embeds Cencora inside specialty practices' medication and billing operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Parental Leave
Adoption Assistance
Infertility Coverage
Family Planning Benefits
Behavioral Health Solutions
Professional Development Budget
Training Programs
Company News
Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.
Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.
CVS Health led health insurance providers in Q1, with revenues of $100.4 billion, up 6.2% year on year and beating analyst expectations by 6.3%. The company exceeded full-year EPS guidance estimates. The 12 health insurance provider stocks tracked reported strong Q1 results overall. Revenues beat consensus estimates by 1.4%, whilst next quarter's guidance was in line. Share prices rose 37.4% on average following the earnings announcements. Cencora performed weakest amongst peers, reporting revenues of $78.36 billion, up 3.8% year on year. This fell short of analyst expectations by 3.9%. The stock has remained flat since reporting and currently trades at $303.53. The industry faces tailwinds from an ageing population and improved data analytics, but regulatory scrutiny on pricing and medical cost inflation may impact margins.
Cencora has launched a multi-site pilot of its upgraded Nucleus inventory management solution for specialty physician practices, aiming to improve medication workflow efficiency and inventory visibility. The company has also appointed Samantha Hammock, formerly of Verizon, as chief human resources officer, succeeding Silvana Battaglia. The company's stock trades at $286.13, approximately 18% below the $351 analyst consensus target. Cencora has posted mixed returns, gaining 5.3% over the past week and 6.2% over the past month, whilst declining 15.6% year to date. A key risk flagged by analysts is that debt is not well covered by operating cash flow. Investors will monitor adoption feedback from pilot sites and how the leadership changes affect the company's specialty care operations.
Cencora has launched a multi-site pilot of its enhanced Nucleus inventory management solution across more than 20 specialty physician practice sites. The updated platform combines redesigned physical infrastructure with improved software to help practices manage complex medication workflows more efficiently. Developed with input from customer advisory boards and care providers, the enhanced solution features a modular cabinet design, larger integrated touchscreen, built-in workspace improvements and a unified interface designed to reduce training time. The system provides real-time inventory tracking, demand forecasting and automated billing support. The pilot will evaluate system performance across different practice settings. Pending outcomes, Cencora expects to begin scaling production and installation later this year, with expanded availability planned for existing and new customers.